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or COPD in picking up newly diagnosed CHF is approximately 20%. This group of 
patients presents a substantial therapeutic opportunity for the initiation and chronic 
administration of ACEI and BB therapy as well as other CHF management strategies. 
1013-76 Influence of Creatinine on Plasma Concentrations and 
the Prognostic Value of N-Terminal Pro-BNP in Severe 
Chronic Heart Failure: Data From a Substudy of the 
COPERNICUS Trial 
Franz S. Hartmann, lldiko Amann-Zalan, Silke Hoersch, Hugo A. Katus, Medicine Klinik 
II, UKL, Luebeck, Germany, lnnere Medizin Ill, Medicine University Heidelberg, 
Heidelberg, Germany 
Background: The impact of creatinine levels on plasma concentrations as well as the 
prognostic value of N-terminal proENP (pmBNP) was evaluated in patients with symp- 
toms of congestive heart failure (CHF) at rest or on minimal exertion. 
Methods: Plasma concentrations of proBNP, were measured using a newly developed 
sandwich ELISA in a subgroup of 1048 patrents of the European part of the COPERNI- 
CUS study. 
Results: ProBNP baseline values, mean*SD. were 74lilO16 pmol/L in patients with ele- 
vated (a=125 U/L) creatinine, compared to 403~461 pmollL in patients with normal 
(cl25UiL) creatinine (p=O.OOOl, Wilcoxon P-sample test). A significant positive correla- 
tion (r= 0.35, p=O.OOOl, Pearson Correlation Coefficient) was detected between proBNP 
and creatinine. By multivariate Cox regression, NT-proBNP but not creatinine was a pow- 
erful independent indicator of subsequent cardiac events. A statistical significant creati- 
nine-proBNP interaction could be detected (p=O.O2 for the primary endpoint), indicating 
that the prognostic value of proBNP for survival is not constant Over the range of creati- 
nine. Risk ratios for proBNP levels below vs. above median are indicated in the table 
according to quartiles of baseline creatinine. 
Conclusions: In patients wtth advanced CHF treated wrthin the COPERNICUS study, 
proBNP plasma concentrations are related to creatinine both at baseline and during 
treatment. In addihon, baseline creatinine levels seam to influence the prognostic value 
of proBNP concentrations. 
Risk Ratios for all-cause mortalrty for proBNP (below median : above median) according to 
creatimne 
Creatinine quartile Risk ratio 95% C.I. P-value (log rank test) 
Quartile 1 (cl11 U/L) 2.51 1.01-6.21 0.0397 
Quartile 2+3 (1 II-146 U/L) 3.29 1.57-6.69 0.0006 
Quartile 4 (>148 U/L) 3.64 1.27-I 0.44 0.0103 
1013-77 Extent and Not Nature of Dysfunctional Myocardium Is 
the Main Determinant of B-Type Natriuretic Peptide in 
Patients With lschemic Left Ventricular Dysfunction 
Charles A. Nelson, Jane McCrohon, Stephen Rose, Thomas H. Marwick, University of 
Queensland, Brisbane, Australia 
Background: B-type Natrfuretic Peptide (BNP) reflects LV filling pressures, but the 
determinants of BNP release in ischemic LV dysfunction (eg. roles of global LV size and 
function, regional wall stress and myocardial viability) are unclear. 
Methods: BNP (Biosite, San Diego) was measured in 32 pts (age 45 -75) with LV dys- 
function after infarction. MRI was used to measure LVEDV, LVESV and LVEF, and iden- 
tify dysfunctional myocardium. The LV was divided into 64 subsegments after dividing 
the 16 segts into 4 layers reflecting the transmural extent of infarction. Late contrast 
enhancement was used to identify infarcted (IM-late enhancement), viable (VM-regional 
dysfunction with no enhancement), and normal myocardium (NM). LV systolic global wall 
stress (WS) was calculated from LVESV, LV mass (both indexed by division with body 
surface area) and systolic BP. 
Results: Thestrongest correlation of BNP was with total dysfunctional myocardium (ie 
numbers of segts with abnormal function). This was superior to correlations with infarcted 
and viable myocardium, and clearly superior to correlations with LVESV, LVEF and WS 
(Table). There was no meaningful correlation with a range of clinical factors. In a multi- 
variate model, the only independent predictor of BNP was total dysfunctional myocar- 
dium (beta 0.63, pcO.0001) 
Correlation Between Log BNP and Other Parameters 
Total Dysfunctional IM VM NM LVES LVEF WS 
Myocardium V 
r 0.640 0.580 0.561 -0.640 0.406 0.419 0.397 
p <0.0001 <o.ooo 0.001 co.000 0.001 0.001 0.066 
1 1 
Conclusion: In patients with ischemic LV dysfunction, the amount of dysfunctional myo- 
cardium (rather than its nature) is an important determinant of BNP more so than LVEF 
or even ws. 
1013-78 Can the Presence of an S3 Predict Elevated B-Type 
Natriuretic Peptide Levels? 
Greaorv M. Marcus Andrew D. Michaels, Teresa A. DeMarco, Kanu Chatterjee. 
University of California, San Francisco, San Francisco, CA 
Background: B-type natriuretic peptide (BNP) has been shown to be a sensitive and 
specific marker of congestive heart failure (CHF). Levels of this hormone demonstrate 
accurate correlation with left ventricular end-diastolic pressure and predict prognosis in 
heart failure patients. The presence of a third heart sound in older adults is thought to 
reflect left ventricular volume overload, with recent data demonstrating an adverse prog- 
nosis in CHF patients with this physical finding. An association between BNP levels and 
the presence of an 53 has not previously been studfed. We hypothesized that ausculta- 
tion of an S3 in older patients reflects elevated BNP levels. 
Methods: BNP levels (Biosite, San Diego, CA) ware measured in 75 consecutive 
patients visiting a general cardiology outpatient clinic. On the day that BNP was mea- 
sured, a single experienced cardiologist (K.C.) blinded to BNP levels auscultated each 
patient in the supine and left lateral decubitus positions. The patients’ primary diagnoses 
were determined by chart review, and the presence or absence of overt CHF was deter- 
mined clinically on the day of the examination. 
Results: 77% of the patients were male, 55% had coronary artery disease, and 11% had 
dilated cardfomyopathy. The mean age was 73*13 years and the mean BNP level was 
263i257 pglml. 26% of patients were diagnosed with overt CHF, and 23% ware found to 
have an S3. The mean BNP level of those with oven CHF was 502 pglml, and the mean 
BNP level of those without overt CHF was 165 pg/ml (p=O.O00006). The mean BNP level 
of those with an S3 was 505 pg/ml, and the mean BNP level of those without an S3 was 
192 pgiml (p=O.O0007). All patients with an 53 had overt CHF. A BNP level > 100 pg/ml 
was 100% sensitive and 50% specific for the presence of overt CHF. The prasence of an 
53 was 46% sensitive and 100% specific for a BNP level > 100 pgiml. 
Conclusiorr In an elderly patient population with cardiovascular disease, the presence 
of an S3 is 100% specific for BNP levels > 100 pglml. 
1013-79 Bedside B-Type Natriuretic Peptide in the Emergency 
Diagnosis of Systolic and Nonsystolic Heart Failure: 
Results From the Breathing Not Properly (BNP) 
Multinational Study 
Alan S. Maisel Radmila Kazanegra, Peter A. McCullough, James McCord, Richard M. 
Nowak, Judd E. Hollander, Alan H. Wu, Philippe Due, Torbjorn Omland, Alan B. Storrow, 
Padma Krfshnaswamy, William T. Abraham, Paul Clopton, Philippe Gabriel Steg, Arne 
Westheim, Cathrine Wold Knudsen, Howard C. Herrmann, Veterans Administration 
Healthcare System, San Diego, CA, University of Missouri-Kansas City School of 
Medicine, Truman Medical Center, Kansas City, MO 
Background Preserved systolic function is increasing common in patients presenting 
with symptoms of congestive heart failure (CHF), but is still difficult to diagnose. This 
study examines B-type natriuretic peptide (BNP) levels in patients with systolic versus 
non-systolic dysfunction presenting with shortness of breath. Methods: The BNP Multi- 
national Study was a seven center, prospective study of 1566 patients who presented 
with acute dyspnea and had BNP measured upon arrival.. A subset of 452 patients with a 
final adjudicated diagnosis of congestive heart failure who underwent echocardiography 
within thirty days of their visit to the emergency department ware evaluated. An ejection 
fraction of greater than 45% was defined as non-systolic CHF. Results: Of the 452 
patients with a final diagnosis of congestive head failure, 165 (36.5%) had preserved left 
ventricular function on echocardiography while 207 (63.5%) had systolic dysfunction. 
Patients with non-systolic heart failure (NS-CHF) had significantly lower BNP levels than 
those with systolic heart failure (SCHF)(413 pg/ml versus 621 pg/ml p <O.OOl). As the 
severity of head failure worsened by NYHA, the percentage of S-CHF increased whrle 
the percentage of NS-CHF decreased. When patients NS-CHF were compared to 
patients without CHF (n=770). a BNP value of 100 pg/ml had a sensitivrty of 86%, a neg- 
ative predictive value of 96%, and an accuracy of 75% for detecting abnormal diastolic 
dysfunction. Using Logistic regression to differentiate S-CHF from NS-CHF. BNP entered 
first as the strongest predictor followed by oxygen saturation, history of myocardial infarc- 
tion, and heart rate.Conclusions We conclude that NS-CHF is common in the setting of 
the emergency department and that differentiating NS-CHF from S-CHF IS difficult in this 
setting using traditional parameters. While BNP levels add modest discrimmatory value 
rn differentiating NS-CHF from S-CHF, its major role is still the separation of patients with 
CHF from those without CHF. 
1013-80 N-T Pro-BNP and the Diagnosis of Heart Failure: A 
Pooled Analysis of Three European Epidemiological 
Studies 
Theresa A. McDonaah, llan Raymond, Stephan Holmer. Andreas Luchner, Per 
Hildebrandt, Henry J. Dargie, University of Glasgow, Glasgow, Umted Kingdom 
BackgroundMany studies have reported the efficacy of BNP in dragnosing heart failure 
(HF) using the optimum concentration on ROC analysis as their cut-point However, in 
routine clinical practice a cut-point reflecting abnormality has to be applied. This study 
reports the use of NT-pro_BNP (proBNP) in detecting HF in a metanalysis of three epide- 
mrological studies. 
Methods: 3052 subjects were pooled from three European Population-Based studies of 
LV Dysfunction, which had collected compatible clinical information and measured 
plasma proBNP (MTP assay Roche) In particular 549 subjects were normal i.e.free of 
cardiovascular disease. As proBNP concentrations mse with age and were higher in 
women ,an abnormal proBNP was defined as >95th centile.corrected for age and sex. HF 
was defined as a LVEF by echo cardiography 4.5the centile for the normal range of 
each centre and symptoms of dyspnoea and/or loop diuretrc therapy. 
Results: The prevalences of HF and LVD were 3.1% and 10% The median concentra- 
